Insilico Medicine– tag –
-
Insilico Medicine Nominates ISM9077, Potential First-in-Class AI-Designed Target Y Inhibitor, as Preclinical Candidate for Ocular, Inflammatory, and Aging Disorders
Barchart.com (Insilico Medicine Press Release) Hong Kong Overview Insilico Medicine nominated ISM9077, a potential first-in-class Target Y inhibitor, as a preclinical candidate (PCC) for ocular diseases, inflammatory disorders, and aging... -
Asia-Pacific AI Drug Discovery Platforms Mature, Achieving Key Clinical Milestones
BioPharma APAC Asia-Pacific Overview AI drug discovery platforms in the Asia-Pacific region are demonstrating significant clinical traction, with Hummingbird Bioscience initiating patient dosing for its HER3-targeted ADC and Insilico Med... -
Isomorphic Labs Secures $2.9 Billion in Partnerships with Eli Lilly and Novartis, Validating AI Drug Discovery Platform
GeneOnline Taiwan Overview Isomorphic Labs, a Google DeepMind spin-out, has solidified its AI drug discovery platform's value through significant partnerships totaling $2.9 billion with Eli Lilly ($1.7B) and Novartis ($1.2B). Concurrentl... -
AI Drug Discovery Cuts Development Time to 18 Months, Insilico Medicine Achieves 99% Cost Reduction for Novel Candidates
BCC Research USA Overview AI is dramatically accelerating drug discovery, shortening the timeline from a decade to under 18 months, with Insilico Medicine identifying a drug candidate for just $2.6 million—a 99% cost saving. This rapid a... -
Insilico Medicine Advances AI-Designed Drug to Phase III for IPF, with 31 Candidates Beyond Preclinical Stage
Forbes USA Overview Generative biology, leveraging AI to design drug molecules, proteins, and DNA, is pushing AI-designed candidates into human trials. Insilico Medicine has a Phase III drug for idiopathic pulmonary fibrosis and 31 devel... -
Generative AI Revolutionizes Pharmaceutical Research: Accelerating Drug Discovery from Years to Months
Generative AI in Drug Discovery USA Overview Generative AI is profoundly transforming pharmaceutical research, primarily through de novo drug design, protein structure prediction, and biologics design. It enables the computational genera... -
Insilico Medicine’s AI-Driven Pan-TEAD Inhibitor ISM6331 Receives FDA Fast Track Designation for Advanced Mesothelioma, Accelerating Development
Insilico Medicine Press Release USA Overview Insilico Medicine announced that its AI-driven pan-TEAD inhibitor, ISM6331, developed using the Chemistry42 platform, received Fast Track Designation from the FDA for advanced malignant pleura... -
AI Transforms Drug Discovery: Generative AI Accelerates Molecule Design to Clinical Prediction, Reducing R&D Costs and Risks
World Pharma Today Unknown Overview AI, particularly generative AI, is fundamentally transforming drug discovery in 2026 by accelerating target identification, molecule design, and outcome prediction. AI-driven platforms computationally ... -
AI Drug Discovery Enters “Clinical Proof Era” in 2026 with Insilico’s Rentosertib in Phase 3 and Isomorphic Labs’ IsoDDE Nearing Clinical Entry
PharmaADC Unknown Overview The article highlights 2026 as the "era of clinical proof" for AI drug discovery, exemplified by Insilico Medicine's AI-developed rentosertib entering Phase 3 trials for idiopathic pulmonary fibrosis (IPF) in J... -
Takeda Partners with Insilico Medicine in $600 Million AI Drug Discovery Deal, Including $60 Million Upfront Payment
Fierce Pharma Asia USA Overview Takeda Pharmaceutical has signed a strategic partnership with AI drug discovery company Insilico Medicine, potentially valued at up to $600 million, including a $60 million upfront payment. Takeda will lev...
